“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Kidney Cancer · 15.03.2022 · 6 (1) · 3-9
DOI: 10.3233/kca-210010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Cancer, online erschienen am 30.12.2021. Verfasst von Hannah Bell und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan School of Medicine, Ann Arbor MI, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The Southwest Oncology Group (SWOG)1931 trial, also known as PROBE (ClinicalTrials.gov Identifier: NCT04510597) is a phase III study evaluating the role of cytoreductive nephrectomy (CN) in metastatic renal cell cancer (RCC). Kidney cancer presenting with synchronous metastases has demonstrated shorter survival outcome compared to the patients relapsing with metastases after nephrectomy. Previously, CN has been associated with survival improvement when interferon-based systemic therapy was used. In the setting of antivascular therapy sunitinib, a prospective randomized clinical trial demonstrated no benefit of CN. Immune checkpoint-based combination therapy has now become the standard-of-care in the frontline setting for RCC. The role of nephrectomy or primary resection has not been evaluated in the setting of immune checkpoint-based systemic therapy. The sequence and optimal timing of nephrectomy is also not established. The PROBE study design attempts to answer the question whether CN has an impact on overall survival outcomes in RCC within the context of immune checkpoint-based combination regimens. The study requires starting with systemic therapy; any one of the FDA approved immunotherapy-based regimens at the time the study was activated are permitted. The disease status and response are evaluated at 9–12 weeks of therapy and then consented patients are randomized 1:1 to receive CN or to continue systemic therapy. The patients who have rapid disease progression are considered ineligible for randomization as they need a switch in systemic therapy. Both groups should continue systemic therapy as long as they are tolerating the treatment and continuing to derive clinical benefit. Quality-of-life, tumor genomic testing, microbiome, radiomics and circulating tumor DNA assessments as predictive biomarkers are planned as study correlatives. The study hypothesis is that CN will improve OS in synchronous metastatic RCC when surgery is performed after starting systemic immune checkpoint-based combination therapy. A potential mechanism leading to improved survival is the broader antigen spread and higher neoantigen load enabled by the primary tumor enhancing the efficacy of the immune therapy. CN after initial systemic therapy would help select the patient subset most likely to benefit and will potentially enable eradication of immune resistant clones within the primary tumor.
Autor:innen und Institutionen
- University of Michigan School of Medicine, Ann Arbor MI, USA.
- Department of Urology, University of Michigan, Ann Arbor MI, USA.
- Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA.
- University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
- Division of Urology, Cedars Sinai Cancer Center, Los Angeles CA, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Bell, H., Cotta, B. H., Salami, S. S., Kim, H., & Vaishampayan, U. (2022). “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer, 6(1), 3-9. https://doi.org/10.3233/kca-210010
Vancouver
Bell H, Cotta BH, Salami SS, Kim H, Vaishampayan U. “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer. 2022;6(1):3-9. doi:10.3233/kca-210010
BibTeX
@article{Bell2022,
author = {Bell, Hannah and Cotta, Brittney H and Salami, Simpa S and Kim, Hyung and Vaishampayan, Ulka},
title = {“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer},
journal = {Kidney Cancer},
year = {2022},
volume = {6},
number = {1},
pages = {3--9},
doi = {10.3233/kca-210010}
}
EUVIMED